ICLE 2022 | Evaluating responses to immunotherapies with non-invasive tools
Despite numerous tools to measure minimal disease residue (MRD) and other metrics in multiple myeloma, assessing the efficacy of immunotherapies remains underdeveloped. Angela Krackhard, MD, PhD, Technical University of Munich, Munich, Germany, comments on remaining barriers to implement non-invasive imaging tools as predictive and surrogate markers to evaluate T-cell therapies. Imaging T-cells such as CD8 cells without T-cell depletion remain a major priority and using fragmented antibodies as opposed to whole antibodies can visualize T-cell responses more effectively, as well as target CD2 and CD7, which are highly expressed on activated T-cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
